Table 1 Patient characteristics

Sex

 Male/Female

381 (72.3)/146 (27.7)

Age at start of first ICI cycle (in years)

70 [17-90]

Primary tumor localization

 Respiratory tract/Head and neck/Digestive tract

214/88/70

 Urinary tract/Hepatocellular, Biliary Tract/Female genital organs

67/35/24

 Skin/Breast/Others

15/11/3

Comorbidities* (prior to the initiation of ICI therapy)

315 (59.8)

Immune-related comorbidities** (prior to initiation of ICI therapy)

62 (11.8)

ICI treatment line

 First or adjuvant

291 (55.2)

 Second

151 (28.7)

 Third or later

85 (16.2)

ICI agent

 Anti-PD-1 antibody (nivolumab/pembrolizumab)

216/204

 Anti-PD-L1 antibody (atezolizumab/durvalumab/avelumab)

106/15/6

 Anti-CTLA-4 antibody (ipilimumab)

56

ICI Combination regimen

 Anti-PD-(L)1 antibody Monotherapy

302

 Anti-PD-(L)1 antibody and Chemotherapy

192

 Anti-CTLA-4 antibody and Anti-PD-(L)1 antibody

56

 Anti-CTLA-4 antibody and Anti-PD-(L)1 antibody and Chemotherapy

23

ICI Combination regimen; Chemotherapy

 Cytotoxic Drugs; platinum/taxane/5-FU

  pemetrexed/etoposide

137/37/30

46/30

 Antiangiogenic Agents; bevacizumab/lenvatinib/axitinib

44/14/2